Osteopore (ASX:OSX) has signed two initial term sheets to license bioactive technology that accelerates bone and tissue regeneration.

The technology is based on a bioactive compound that aims to speed up bone and tissue growth significantly, potentially leading to faster recovery times, fewer complications, and lower healthcare costs.

Osteopore will also lead the first human clinical trial to evaluate the safety, efficacy, and long-term benefits of the compounds in various bone growth applications.

The biologics market is expected to be worth $US420.5B by 2025, representing a significant opportunity for Osteopore.